Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications
PR-104A is a dual hypoxia/nitroreductase gene therapy prodrug by virtue of its ability to undergo either one- or two-electron reduction to its cytotoxic species. It has been evaluated extensively in pre-clinical GDEPT studies, yet off-target human aldo-keto reductase AKR1C3-mediated activation has l...
Saved in:
Main Authors: | Amir Ashoorzadeh (Author), Alexandra M. Mowday (Author), Christopher P. Guise (Author), Shevan Silva (Author), Matthew R. Bull (Author), Maria R. Abbattista (Author), Janine N. Copp (Author), Elsie M. Williams (Author), David F. Ackerley (Author), Adam V. Patterson (Author), Jeff B. Smaill (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
by: Maria R. Abbattista, et al.
Published: (2021) -
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
by: William A. Denny
Published: (2022) -
Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling
by: Victoria Jackson-Patel, et al.
Published: (2022) -
Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization
by: Rebecca Nofsinger, et al.
Published: (2014) -
Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
by: Fu Li, et al.
Published: (2019)